ASXCeasing to be a substantial holder from MFG
other announcement
CHM
Pharmaceuticals, Biotechnology & Life Sciences
Chimeric Therapeutics
- Short interest
- 0.00%
- −0.13 pp 30d
- as of 11 May 2026
- Reported shorts
- 1
- Shares on issue
- 51.822M
Chimeric Therapeutics (CHM) News
Latest articles and price-sensitive announcements with AI sentiment classification.
Notice of initial substantial holder from MFG
other announcement
Final Director's Interest Notice - LR
other announcement
Final Director's Interest Notice - BG
other announcement
Initial Director's Interest Notice - RM
other announcement
FY2026 Annual Report, creditor update and Board changes
other announcement
Google NewsChimeric Therapeutics Applies to Quote 29.3 Million Shares Following Convertible Note Conversion - Kalkine
Chimeric Therapeutics Applies to Quote 29.3 Million Shares Following Convertible Note Conversion Kalkine
Application for quotation of securities - CHM
other announcement
Chimeric Therapeutics' Market Cap Drops To AU$473k Leaving Insiders With Losses - simplywall.st
Chimeric Therapeutics' Market Cap Drops To AU$473k Leaving Insiders With Losses simplywall.st
Application for quotation of securities - CHM
other announcement
Why Biotech Stock Chimeric Therapeutics (ASX:CHM) Is Pursuing a Different Approach to Cancer Treatment - Kalkine
Why Biotech Stock Chimeric Therapeutics (ASX:CHM) Is Pursuing a Different Approach to Cancer Treatment Kalkine
Application for quotation of securities - CHM
other announcement
Chimeric Therapeutics (ASX: CHM) Rebounds 16.67%: Can the Cell Therapy Story Find a New Direction? - Kalkine
Chimeric Therapeutics (ASX: CHM) Rebounds 16.67%: Can the Cell Therapy Story Find a New Direction? Kalkine
Appendix 4E and Preliminary Final Report
other announcement
Chimeric Therapeutics (ASX:CHM) Shares Under Pressure as Cell Therapy Strategy Resets - Kalkine
Chimeric Therapeutics (ASX:CHM) Shares Under Pressure as Cell Therapy Strategy Resets Kalkine
CHM ceases enrolment in Phase 1 trial and Company update
other announcement
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Chimeric Therapeutics (ASX:CHM) Shares Rise Today – Here’s Why - Kalkine
Chimeric Therapeutics (ASX:CHM) Shares Rise Today – Here’s Why Kalkine
Chimeric receives $1.62M advance on FY26 R&D tax incentive
other announcement
KalkineChimeric Therapeutics Reports Promising Progress in CDH17 CAR-T and CORE-NK Cancer Therapy Trials
Chimeric Therapeutics has shared important updates on its clinical trials for cutting-edge cell therapies targeting multiple cancer types. The company is leading the global development of the first CDH17 CAR-T therapy in clinical trials, potentially transforming treatment options for patients. These advancements are likely to attract investor attention due to their significant market implications. Key Points Chimeric Therapeutics Ltd (CHM) Initiated several Phase 1/2 clinical trials for CDH17...
Chimeric Therapeutics Converts 1.55 Million Convertible Notes Into Ordinary Shares, Boosting Share Capital
On 22 July 2026, Chimeric Therapeutics Limited (ASX: CHM) announced the successful conversion of 1,550,387 ordinary fully paid shares following the conversion of convertible notes. This conversion, approved by shareholders at an extraordinary general meeting (EGM) on 17 April 2026, was finalized on the announcement date. The transaction increases the company’s total quoted capital to 59,459,543 ordinary shares, marking a significant expansion of its issued equity base. Key Highlights Chimer...
Chimeric Therapeutics (ASX:CHM) Shares Rise 9%: What Drove the Biotech Stock Higher? - Kalkine
Chimeric Therapeutics (ASX:CHM) Shares Rise 9%: What Drove the Biotech Stock Higher? Kalkine
CHM CDH17 Phase 1 clinical trial update - New DL 3 data
other announcement
Is Chimeric Therapeutics (ASX: CHM) Positioning for a Biotechnology Recovery? - Kalkine
Is Chimeric Therapeutics (ASX: CHM) Positioning for a Biotechnology Recovery? Kalkine
Chimeric Therapeutics Limited (ASX:CHM): Is This CAR-T Biotech Story Still Building Momentum? - Kalkine
Chimeric Therapeutics Limited (ASX:CHM): Is This CAR-T Biotech Story Still Building Momentum? Kalkine
What's Driving Chimeric Therapeutics' (ASX: CHM) Share Price? - Kalkine
What's Driving Chimeric Therapeutics' (ASX: CHM) Share Price? Kalkine
Appointment of Financial Adviser for Strategic Review
other announcement
Chimeric Therapeutics (ASX: CHM): Could Cancer-Therapy Stock CHM Be Back on Biotech Watchlists? - Kalkine
Chimeric Therapeutics (ASX: CHM): Could Cancer-Therapy Stock CHM Be Back on Biotech Watchlists? Kalkine
Chimeric Therapeutics (ASX:CHM) Shares Jump 15% Today- Here’s Why? - Kalkine
Chimeric Therapeutics (ASX:CHM) Shares Jump 15% Today- Here’s Why? Kalkine
Insider Buyers At Chimeric Therapeutics Likely Disappointed With 18% Slide - simplywall.st
Insider Buyers At Chimeric Therapeutics Likely Disappointed With 18% Slide simplywall.st